health - "report"

Related Articles Rehmannia inhibits adipocyte differentiation and adipogenesis. Biochem Biophys Res Commun. 2008 Jun 27;371(2):185-90 Authors: Jiang L, Zhang NX, Mo W, Wan R, Ma CG, Li X, Gu YL, Yang XY, Tang QQ, Song HY Rehmannia glutinosa, a Traditional Chinese Medicine (TCM), has been used to increase physical strength. Here, we report that Rehmannia glutinosa extract (RE) inhibits adipocyte differentiation and adipogenesis. RE impairs differentiation of 3T3-L1 preadipocytes in a dose-dependent manner. At the molecular level, treatment with RE inhibits expression of the key adipocyte differentiation regulator C/EBPbeta, as well as C/EBPalpha and the terminal marker protein 422/aP2, during differentiation of preadipocytes into adipocytes. Additionally, RE inhibits the mitotic clonal expansion (MCE) process of adipocyte differentiation, and RE prevents localization of C/EBPbeta to the centromeres. RE also prevents high fat diet (HFD) induced weight ga

Related Articles PLAP-1/asporin inhibits activation of BMP receptor via its leucine-rich repeat motif. Biochem Biophys Res Commun. 2008 Jun 27;371(2):191-6 Authors: Tomoeda M, Yamada S, Shirai H, Ozawa Y, Yanagita M, Murakami S We previously identified the novel gene, periodontal ligament-associated protein-1 (PLAP-1)/asporin and reported that PLAP-1/asporin inhibited bone morphogenetic protein-2 (BMP-2)-induced cytodifferentiation of periodontal ligament (PDL) cells probably by direct interaction with BMP-2. Here, we elucidated the detailed regulatory mechanism of this protein on BMP-2-induced cytodifferentiation of PDL cells. Recombinant PLAP-1/asporin inhibited BMP-2-induced cytodifferentiation of PDL cells and competitively prevented BMP-2 from binding to the BMP receptor-IB (BMPR-IB), resulting in inhibition of BMP-dependent activation of Smad proteins. The induction of mutation to the leucine-rich repeat (LRR) motif, especially LRR5, within PLAP-

Related Articles Molecular characterization of two novel isoforms and a soluble form of mouse CLEC-2. Biochem Biophys Res Commun. 2008 Jun 27;371(2):180-4 Authors: Xie J, Wu T, Guo L, Ruan Y, Zhou L, Zhu H, Yun X, Hong Y, Jiang J, Wen Y, Gu J CLEC-2 was first identified by sequence similarity to C-type lectin-like molecules with immune functions. Recently, human CLEC-2 has been reported as a receptor for the platelet-aggregating snake venom toxin rhodocytin and the endogenous sialoglycoprotein podoplanin. It has also been reported to facilitate the capture of HIV-1. However, investigation of mouse CLEC-2 (mCLEC-2) has little progressed after its identification. In this study, we identified two novel splicing variants of mCLEC-2 derived from omission of exon 2 and 2/4, respectively. These two variants had different expression profiles and subcellular localization from full-length mCLEC-2. Moreover, we observed that full-length mCLEC-2 could be cleaved p

A fast-food giant is unveiling a decadent new burger made of the highest-quality beef and exotic garnishes. The pricetag: $200. While customers say it's delicious, critics say it's simply not in good taste. Mark Philips reports.

The largest assessment of people with adult muscular dystrophy has identified risk factors that can lead to sudden death for individuals with the most common form of this disease. The results of the multicenter study, lead by the Indiana University School of Medicine, are reported in the June 19 issue of the New England Journal of Medicine.

NEW YORK (Reuters Health) - Risedronate, better known by the brand name Actonel, is effective for maintaining or improving the bone strength of women who have had chemotherapy for breast cancer, researchers report.

A new report from the National Center on Addiction and Substance Abuse echoes recent federal reports claiming that marijuana has become more potent over the past decade and a half, adding that treatment admissions for marijuana problems increased dramatically during the same time frame.

Despite billions in U.S. antidrug aid aimed largely at eradication, Colombia's coca crop increased by 27 percent in 2007.

HealthDay - WEDNESDAY, June 18 (HealthDay News) -- French doctors havereported a possible new side effect associated with the cancer drugGleevec (imatinib), widely used for the treatment of chronic myeloidleukemia and gastrointestinal stromal tumors.

Risedronate, better known by the brand name Actonel, is effective for maintaining or improving the bone strength of women who have had chemotherapy for breast cancer, researchers report.